AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT04673617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
Study identification
- NCT ID
- NCT04673617
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- AB-101 Drug
- Bendamustine Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Interleukin-2 Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2021
- Primary completion
- Oct 5, 2025
- Completion
- Oct 5, 2025
- Last update posted
- Apr 2, 2026
2021 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Artiva Clinical Trial Site | Birmingham | Alabama | 35249 | — |
| Artiva Clinical Trial Site | Tucson | Arizona | 85719 | — |
| Artiva Clinical Trial Site | Orange | California | 92868 | — |
| Artiva Clinical Trial Site | San Diego | California | 92093 | — |
| Artiva Clinical Trial Site | Gainesville | Florida | 32608 | — |
| Artiva Clinical Trial Site | Atlanta | Georgia | 30342 | — |
| Artiva Clinical Trial Site | Chicago | Illinois | 60612 | — |
| Artiva Clinical Trial Site | Iowa City | Iowa | 52242 | — |
| Artiva Clinical Trial Site | Wichita | Kansas | 67214 | — |
| Artiva Clinical Trial Site | Louisville | Kentucky | 40241 | — |
| Artiva Clinical Trial Site | Detroit | Michigan | 48201 | — |
| Artiva Clinical Trial Site | Lake Success | New York | 11042 | — |
| Artiva Clinical Trial Site | New York | New York | 11021 | — |
| Artiva Clinical Trial Site | Columbus | Ohio | 43214 | — |
| Artiva Clinical Trial Site | Portland | Oregon | 97239 | — |
| Artiva Clinical Trial Site | Philadelphia | Pennsylvania | 19107 | — |
| Artiva Clinical Trial Site | Philadelphia | Pennsylvania | 19111 | — |
| Artiva Clinical Trial Site | Providence | Rhode Island | 02903 | — |
| Artiva Clinical Trial Site | Dallas | Texas | 75246 | — |
| Artiva Clinical Trial Site | Salt Lake City | Utah | 84112 | — |
| Artiva Clinical Trial Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04673617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04673617 live on ClinicalTrials.gov.